NIAID PRECLINICAL DEVELOPMENT SUPPORT - IMMUNOAFFINITY PURIFICATION OF HIV-1 ENV PROTEINS

NIAID 临床前开发支持 - HIV-1 ENV 蛋白的免疫亲和纯化

• 批准号: 10610267
• 负责人: THOMAS VANCOTT
• 金额: $ 34.63万
• 依托单位: ADVANCED BIOSCIENCE LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-15 至 2021-08-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10610267
• 关键词: Contracts; Development; Documentation; HIV-1; Investigational Drugs; Investigator-Initiated Research; National Institute of Allergy and Infectious Disease; Phase; Preclinical Testing; Production; env Gene Products; flexibility; preclinical development; research clinical testing; research study

This contract will provide NIAID with a broad and flexible range of nontraditional, proactive and developmentally-oriented capabilities to provide preclinical development support for promising products when such products emerge from investigator-initiated research studies. These capabilities will allow NIAID to more rapidly and efficiently close development and production gaps. Activities include but are not limited to small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submission for Phase I, II, and III clinical testing. In particular this project will support the immunoaffinity purification of HIV-1 envelope proteins.

该合同将为NIAID提供广泛而灵活的非传统，主动和以开发为导向的能力，为有前途的产品提供临床前开发支持，当这些产品从制药商发起的研究中出现时。这些能力将使NIAID能够更快、更有效地缩小开发和生产差距。活动包括但不限于小规模生产、临床前试验和文件编制，以提交研究性新药（IND）进行I、II和III期临床试验。特别是，该项目将支持HIV-1包膜蛋白的免疫亲和纯化。